Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

Mutagenic DNA Lesions in Normal Hematopoietic Stem Cells Persist for Years Causing Distinct Patterns of Mutation

Blood (2024) 144 (Supplement 1): 2673.

https://doi.org/10.1182/blood-2024-208773

Published: 2024

Journal Articles

The Pathogenesis of Therapy-Related Myeloid Neoplasms from TP53 -Mutant Clonal Hematopoiesis

Jonas Fullin, Ebru Topçu, Roman R. Schimmer, Nancy Klemm, Karolina Zielinska, Christian Koch, Francisco Caiado, Cyril Doerdelmann, Melissa Lock, Joelle Tchinda, Markus G. Manz, Massimo Lopes, Steffen Boettcher

Blood (2024) 144 (Supplement 1): 41.

https://doi.org/10.1182/blood-2024-205209

Published: 2024

Journal Articles

Somatic TP53 Mutations Rescue the Hematopoietic Stem and Progenitor Cell Defect at the Expense of Increased Risk for Myeloid Malignancies in ERCC6L2 -Associated Inherited Bone Marrow Failure Syndrome

Roman R. Schimmer, Nancy Klemm, Ebru Topçu, Jonas Fullin, Karolina Zielinska, Cyril Doerdelmann, Melissa Lock, Milena Treacy, Francisco Caiado, Nadja Dietliker, Rahel Schwotzer, Markus G. Manz, Massimo Lopes, Steffen Boettcher

Blood (2024) 144 (Supplement 1): 193.

https://doi.org/10.1182/blood-2024-204925

Published: 2024

Journal Articles

MP0533 (CD33 x CD123 x CD70 x CD3), a Tetra-Specific CD3-Engaging Darpin for the Treatment of Patients with Relapsed/Refractory AML or MDS/AML: Results of an Ongoing Phase 1/2a Study

Blood (2024) 144 (Supplement 1): 2881.

https://doi.org/10.1182/blood-2024-199211

Published: 2024

Journal Articles

MDS-AML Aggregative Risk Classification System ( MARCS ): A Novel, Enhanced Risk Stratification System Derived from the Combined Unsupervised Analysis of 7,480 MDS and AML Patients

Marco Roncador, Fritz Bayer, Jeremy W. Deuel, Jack Kuipers, Markus G. Manz, Steffen Boettcher, Niko Beerenwinkel, Stefan Balabanov

Blood (2024) 144 (Supplement 1): 4307.

https://doi.org/10.1182/blood-2024-203134

Published: 2024

Journal Articles

Reactivation of p53 in TP53 -Y220C Mutant AML: Mechanism of Action and Mechanism-Based Drug Combinations

Bing Z. Carter, Po Yee Mak, Baozhen Ke, Xiaogang Wu, Steffen Boettcher, Lauren B. Ostermann, Andrea Bedoy, Georgina Gener-Ricos, Jayastu Senapati, Courtney D. DiNardo, Anna Puzio-Kuter, Arnold Levine, Michael Andreeff

Blood (2024) 144 (Supplement 1): 4155.

https://doi.org/10.1182/blood-2024-208403

Published: 2024

Journal Articles

All- Trans Retinoic Acid (ATRA) Enhances the Antileukemic Activity of Decitabine By Increasing Proteasomal Degradation of MYC in a p53-Independent Manner

Usama-Ur Rehman, Steffen Boettcher, Michael Lübbert

Blood (2024) 144 (Supplement 1): 5747.

https://doi.org/10.1182/blood-2024-210676

Published: 2024

Journal Articles

Modelling the Evolution of Clonal Hematopoiesis to Myeloid Malignancies Under the Selective Pressure of Anti-Cancer Therapy

Christian Koch, Jonas Fullin, Ebru Topçu, Nancy Klemm, Karolina Zielinska, Monika Hebeisen, Joelle Tchinda, Markus G. Manz, Steffen Boettcher

Blood (2024) 144 (Supplement 1): 5651.

https://doi.org/10.1182/blood-2024-205797

Published: 2024

Journal Articles

PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignancy

Blood (2023) 142 (24): 2079–2091.

https://doi.org/10.1182/blood.2023020331

Published: 2023

Includes: Supplemental data

Journal Articles

Selective Targeting of TP53-Y220C Mutant AML By PC14586 Results in TP53 Wild-Type Conformation and Synergistical Apoptosis Induction By Concomitant Inhibition of Xpo-1, MDM2, or Bcl-2

Bing Z. Carter, Po Yee Mak, Baozhen Ke, Yuki Nishida, Steffen Boettcher, Andrea Bedoy, Lauren B. Ostermann, Courtney D. DiNardo, Anna Puzio-Kuter, Arnold Levine, Michael Andreeff

Blood (2023) 142 (Supplement 1): 2261.

https://doi.org/10.1182/blood-2023-181186

Published: 2023

Journal Articles

TP53 Deficiency in AML Confers Resistance to CAR T-Cells That Can be Overcome By Targeting the Cholesterol or Wnt Pathways

Jan Mueller, Roman Schimmer, Christian Koch, Florin Schneiter, Jonas Fullin, Veronika Lysenko, Renier Myburgh, Laura Volta, Alexandre Theocharides, Kari Kurppa, Benjamin L. Ebert, Timm Schroeder, Markus G. Manz, Steffen Boettcher

Blood (2023) 142 (Supplement 1): 1019.

https://doi.org/10.1182/blood-2023-185567

Published: 2023

Journal Articles

Novel Hypomethylating Agent Ntx-301 Exhibits Anti-Leukemia Activity in Venetoclax-Resistant and TP53-Mutant AML

Bing Z. Carter, Po Yee Mak, Baozhen Ke, Andrea Bedoy, Steffen Boettcher, Lauren B. Ostermann, Elizabeth J. Shpall, Michael Andreeff

Blood (2023) 142 (Supplement 1): 4158.

https://doi.org/10.1182/blood-2023-180051

Published: 2023

Journal Articles

Treatment of a TP53 isogenic AML Cell Line Model with Decitabine and All Trans -Retinoic Acid (ATRA) Targets MYC for Antileukemic Activity in a p53-Independent Fashion

Usama-Ur Rehman, Steffen Boettcher, Michael Lübbert

Blood (2023) 142 (Supplement 1): 5745.

https://doi.org/10.1182/blood-2023-189202

Published: 2023

Journal Articles

MP0533, a CD3-Engaging Darpin Targeting CD33, CD123, and CD70 in Patients with Relapsed/Refractory AML or MDS/AML: Preliminary Results of a Phase 1/2a Study

Thomas Pabst, Mojca Jongen-Lavrencic, Steffen Boettcher, Geert A. Huls, David C. de Leeuw, Philippe Legenne, Mariola Dymkowska, Christiane Andrieu, Oliver Schönborn-Kellenberger, Paul G. Baverel, Zita Arany, Elena Fernandez, Anne Goubier, Vladimir Kirkin, Nicolas Leupin, Marion Subklewe

Blood (2023) 142 (Supplement 1): 2921.

https://doi.org/10.1182/blood-2023-173353

Published: 2023

Journal Articles

Epichaperome inhibition targets TP53- mutant AML and AML stem/progenitor cells

Blood (2023) 142 (12): 1056–1070.

https://doi.org/10.1182/blood.2022019047

Published: 2023

Includes: Supplemental data

Journal Articles

Aging drives Tet2 +/− clonal hematopoiesis via IL-1 signaling

Francisco Caiado, Larisa V. Kovtonyuk, Nagihan G. Gonullu, Jonas Fullin, Steffen Boettcher, Markus G. Manz

Blood (2023) 141 (8): 886–903.

https://doi.org/10.1182/blood.2022016835

Published: 2023

Includes: Supplemental data

Journal Articles

Clonal Dynamics after Haematopoietic Stem Cell Transplantation Using Genome-Wide Somatic Mutations

Michael Spencer Chapman, C. Matthias Wilk, Steffen Boettcher, Emily Mitchell, Kevin J Dawson, Larisa V. Kovtonyuk, Jan Müller, Nicholas Williams, Jyoti Nangalia, Markus G Manz, Peter J. Campbell

Blood (2022) 140 (Supplement 1): 1572–1573.

https://doi.org/10.1182/blood-2022-166701

Published: 2022

Journal Articles

Epichaperome Inhibition Targets Kinase and TP53 Mutant Therapy Resistant AML

Bing Z Carter, Po Yee Mak, Wenjing Tao, Lauren B Ostermann, Yuki Nishida, Naveen Pemmaraju, Steffen Boettcher, Elizabeth J Shpall, Gabriela Chiosis, Georgios Karras, Barbara Wallner, Robert A Morgan, Michael Andreeff

Blood (2022) 140 (Supplement 1): 5930–5931.

https://doi.org/10.1182/blood-2022-158547

Published: 2022

Journal Articles

Polyploidy Is Necessary for Apoptotic Cell Death in TP53 -Mut AML in Response to Polo-like-Kinase 4 (PLK4) Inhibition and Results in Caspase 3 Cleavage

Edward Ayoub, Akhil Marupudi, Yuki Nishida, Rafael Heinz Montoya, Vakul Mohanty, Wencke Walter, Mark R Bray, Tallie Patsilevas, Steffen Boettcher, Ghayas C. Issa, Ken Chen, Torsten Haferlach, Gautam Borthakur, Michael Andreeff

Blood (2022) 140 (Supplement 1): 5941–5943.

https://doi.org/10.1182/blood-2022-170152

Published: 2022

Journal Articles

C-MYC Targeting By Degradation: Novel Dual c-Myc/GSPT1 Degrader GT19715 Induces TP53 -Independent Cell Death in Acute Myeloid Leukemia and Lymphomas

Yuki Nishida, Darah A Scruggs, Edward Ayoub, Tallie Patsilevas, Vivian Ruvolo, Po Yee Mak, Bing Z Carter, Steffen Boettcher, Abhishek Maiti, Qianxiang Zhou, Zhaohui Yang, Honghua Yan, Liandong Ma, Michael Andreeff

Blood (2022) 140 (Supplement 1): 483–484.

https://doi.org/10.1182/blood-2022-164968

Published: 2022

NARROW

Mutagenic DNA Lesions in Normal Hematopoietic Stem Cells Persist for Years Causing Distinct Patterns of Mutation

The Pathogenesis of Therapy-Related Myeloid Neoplasms from TP53 -Mutant Clonal Hematopoiesis

Somatic TP53 Mutations Rescue the Hematopoietic Stem and Progenitor Cell Defect at the Expense of Increased Risk for Myeloid Malignancies in ERCC6L2 -Associated Inherited Bone Marrow Failure Syndrome

MP0533 (CD33 x CD123 x CD70 x CD3), a Tetra-Specific CD3-Engaging Darpin for the Treatment of Patients with Relapsed/Refractory AML or MDS/AML: Results of an Ongoing Phase 1/2a Study

MDS-AML Aggregative Risk Classification System ( MARCS ): A Novel, Enhanced Risk Stratification System Derived from the Combined Unsupervised Analysis of 7,480 MDS and AML Patients

Reactivation of p53 in TP53 -Y220C Mutant AML: Mechanism of Action and Mechanism-Based Drug Combinations

All- Trans Retinoic Acid (ATRA) Enhances the Antileukemic Activity of Decitabine By Increasing Proteasomal Degradation of MYC in a p53-Independent Manner

Modelling the Evolution of Clonal Hematopoiesis to Myeloid Malignancies Under the Selective Pressure of Anti-Cancer Therapy

PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignancy

Selective Targeting of TP53-Y220C Mutant AML By PC14586 Results in TP53 Wild-Type Conformation and Synergistical Apoptosis Induction By Concomitant Inhibition of Xpo-1, MDM2, or Bcl-2

TP53 Deficiency in AML Confers Resistance to CAR T-Cells That Can be Overcome By Targeting the Cholesterol or Wnt Pathways

Novel Hypomethylating Agent Ntx-301 Exhibits Anti-Leukemia Activity in Venetoclax-Resistant and TP53-Mutant AML

Treatment of a TP53 isogenic AML Cell Line Model with Decitabine and All Trans -Retinoic Acid (ATRA) Targets MYC for Antileukemic Activity in a p53-Independent Fashion

MP0533, a CD3-Engaging Darpin Targeting CD33, CD123, and CD70 in Patients with Relapsed/Refractory AML or MDS/AML: Preliminary Results of a Phase 1/2a Study

Epichaperome inhibition targets TP53- mutant AML and AML stem/progenitor cells

Aging drives Tet2 +/− clonal hematopoiesis via IL-1 signaling

Clonal Dynamics after Haematopoietic Stem Cell Transplantation Using Genome-Wide Somatic Mutations

Epichaperome Inhibition Targets Kinase and TP53 Mutant Therapy Resistant AML

Polyploidy Is Necessary for Apoptotic Cell Death in TP53 -Mut AML in Response to Polo-like-Kinase 4 (PLK4) Inhibition and Results in Caspase 3 Cleavage

C-MYC Targeting By Degradation: Novel Dual c-Myc/GSPT1 Degrader GT19715 Induces TP53 -Independent Cell Death in Acute Myeloid Leukemia and Lymphomas

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only